COVID-19 and diabetes: What do we know so far?

Exp Biol Med (Maywood). 2022 Aug;247(15):1330-1334. doi: 10.1177/15353702221108914. Epub 2022 Jul 27.

Abstract

Coronavirus disease 2019 (COVID-19) management has been challenging for patients with comorbidities. Patients with diabetes and COVID-19, in particular, have shown severe symptoms and rapid progression of the disease. They also have a high mortality rate compared to the non-diabetic population. The high mortality rate is caused in people with diabetes who are in a pro-inflammatory condition; this could worsen COVID-19. In addition, people with diabetes have circulatory issues and COVID-19 infection can lead to further clotting problems. It is critical to understand the mechanisms underlying the adverse clinical outcomes in patients with diabetes and COVID-19. This review discusses various disease conditions contributing to poor prognosis in diabetic COVID-19 patients such as hyperglycemia, insulin resistance, impaired pancreatic function, and production of advanced glycation end products.

Keywords: COVID-19; SARS-CoV-2; diabetics; hyperglycemia; insulin resistance.

Publication types

  • Review

MeSH terms

  • COVID-19* / complications
  • Comorbidity
  • Diabetes Mellitus* / epidemiology
  • Humans
  • Hyperglycemia*
  • SARS-CoV-2